Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.

N Pearce 1, J Grainger 1, M Atkinson 1, J Crane 1, C Burgess 1, C Culling 1, H Windom 1, R Beasley 1
PMCID: PMC462377  PMID: 2330548

Abstract

A previous New Zealand case-control study of asthma deaths in the 5-45 year age group during 1981-3 found that prescription of fenoterol (by metered dose inhaler) was associated with an increased risk of death in patients with severe asthma. One major criticism of this study was that drug data for the cases and controls came from different sources. A new case-control design has been used to evaluate the same hypothesis, with a different set of asthma deaths, the same source for drug information being used for both cases and controls. This depended on identifying deaths from asthma during 1977-81 from national mortality records, and ascertaining which patients from those who died had been admitted to a major hospital for asthma during the 12 months before death. The study was confined to this subgroup, which accounted for about 20% of all asthma deaths in the areas served by a major hospital. For each of the eligible patients who died four age matched controls were selected from patients admitted to hospital for asthma during the year that the death occurred who had also had an admission for asthma in the previous 12 months. For the 58 cases and 227 control subjects information on prescribed drugs was collected from the hospital records relating to the previous admission. The odds ratio of asthma death in patients prescribed inhaled fenoterol was 1.99 (95% confidence interval 1.12-3.55, p = 0.02). As in the previous study, subgroups defined by markers of chronic asthma severity were also considered. The inhaled fenoterol odds ratio was 2.98 (95% CI 1.15-7.70, p = 0.02) in patients prescribed three or more categories of asthma drugs, 3.91 (95% CI 1.79-8.54, p less than 0.01) in patients with a previous admission for asthma in the past 12 months, and 5.83 (95% CI 1.62-21.0, p = 0.01) in patients prescribed oral corticosteroids at the time of admission. In patients with the most severe asthma (defined by a previous admission for asthma during the past 12 months and prescribed oral corticosteroids at time of admission) the inhaled fenoterol odds ratio was 9.82 (95% CI 2.23-43.4, p less than 0.01). These findings add further support to the hypothesis that inhaled fenoterol increases the risk of death in patients with severe asthma.

Full text

PDF
170

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggestrup S., Henriksen L., Rygg I. H., Lauridsen P. The cardiovascular and respiratory effects of fenoterol in patients after open-heart surgery. J Cardiovasc Surg (Torino) 1980 Jul-Aug;21(4):409–416. [PubMed] [Google Scholar]
  2. Barnes P. J., Chung K. F. PAF antagonists in asthma. Lancet. 1989 May 13;1(8646):1071–1072. doi: 10.1016/s0140-6736(89)92461-6. [DOI] [PubMed] [Google Scholar]
  3. Collins J. M., McDevitt D. G., Shanks R. G., Swanton J. G. The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol. 1969 May;36(1):35–45. doi: 10.1111/j.1476-5381.1969.tb08301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Conolly M. E., Davies D. S., Dollery C. T., George C. F. Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). Br J Pharmacol. 1971 Oct;43(2):389–402. [PMC free article] [PubMed] [Google Scholar]
  5. Copeland K. T., Checkoway H., McMichael A. J., Holbrook R. H. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977 May;105(5):488–495. doi: 10.1093/oxfordjournals.aje.a112408. [DOI] [PubMed] [Google Scholar]
  6. Crane J., Burgess C., Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax. 1989 Feb;44(2):136–140. doi: 10.1136/thx.44.2.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  8. Fenoterol and fatal asthma. Lancet. 1989 May 13;1(8646):1070–1071. [PubMed] [Google Scholar]
  9. Jackson R. T., Beaglehole R., Rea H. H., Sutherland D. C. Mortality from asthma: a new epidemic in New Zealand. Br Med J (Clin Res Ed) 1982 Sep 18;285(6344):771–774. doi: 10.1136/bmj.285.6344.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kendall M. J., Woods K. L., Wilkins M. R., Worthington D. J. Responsiveness to beta-adrenergic receptor stimulation: the effects of age are cardioselective. Br J Clin Pharmacol. 1982 Dec;14(6):821–826. doi: 10.1111/j.1365-2125.1982.tb02043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  12. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976 Feb;103(2):226–235. doi: 10.1093/oxfordjournals.aje.a112220. [DOI] [PubMed] [Google Scholar]
  13. Pearce N., Crane J., Burgess C., Beasley R., Jackson R. Fenoterol and asthma mortality. Lancet. 1989 May 27;1(8648):1196–1197. doi: 10.1016/s0140-6736(89)92768-2. [DOI] [PubMed] [Google Scholar]
  14. Rea H. H., Scragg R., Jackson R., Beaglehole R., Fenwick J., Sutherland D. C. A case-control study of deaths from asthma. Thorax. 1986 Nov;41(11):833–839. doi: 10.1136/thx.41.11.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rønne T. Measles virus infection without rash in childhood is related to disease in adult life. Lancet. 1985 Jan 5;1(8419):1–5. doi: 10.1016/s0140-6736(85)90961-4. [DOI] [PubMed] [Google Scholar]
  16. Sears M. R., Rea H. H., Beaglehole R., Gillies A. J., Holst P. E., O'Donnell T. V., Rothwell R. P., Sutherland D. C. Asthma mortality in New Zealand: a two year national study. N Z Med J. 1985 Apr 24;98(777):271–275. [PubMed] [Google Scholar]
  17. Sears M. R., Rea H. H. Patients at risk for dying of asthma: New Zealand experience. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):477–481. doi: 10.1016/0091-6749(87)90079-0. [DOI] [PubMed] [Google Scholar]
  18. Sears M. R., Rea H. H., de Boer G., Beaglehole R., Gillies A. J., Holst P. E., O'Donnell T. V., Rothwell R. P. Accuracy of certification of deaths due to asthma. A national study. Am J Epidemiol. 1986 Dec;124(6):1004–1011. doi: 10.1093/oxfordjournals.aje.a114470. [DOI] [PubMed] [Google Scholar]
  19. Vathenen A. S., Knox A. J., Higgins B. G., Britton J. R., Tattersfield A. E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. doi: 10.1016/s0140-6736(88)91352-9. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES